TY - JOUR
T1 - Restoration of frontal activation during a treatment with quetiapine
T2 - An fMRI study of blunted affect in schizophrenia
AU - Stip, Emmanuel
AU - Fahim, Cherine
AU - Mancini-Marïe, Adham
AU - Bentaleb, Lahcen Ait
AU - Mensour, Boualem
AU - Mendrek, Adrianna
AU - Beauregard, Mario
N1 - Funding Information:
This work was supported by a grant from Astra-Zeneca Pharmaceuticals and the Fond de la Recherche en Santé du Québec (grant number 005084).
PY - 2005/1
Y1 - 2005/1
N2 - This study investigated changes in cerebral activation related to emotion processing in schizophrenia patients with blunted or flat affect (FA+) during treatment with quetiapine. Using functional magnetic resonance imaging (fMRI), brain activation in 12 FA+ schizophrenia patients during passive viewing of sad film excerpts was studied before and after a median of 5.5-months treatment with quetiapine. Random-effects 'paired sample t-test' analyses of brain activation before quetiapine (contrast=sad-neutral, before-after) revealed significant activation in the brainstem (pons, medulla). After quetiapine, the same contrast showed significant prefrontal activation (BA 9, 10 and 11). Activation of key prefrontal areas involved in emotion processing and significant symptoms improvement as measured by the subjective rating scale and PANSS suggests the potential effect of quetiapine in improving blunted affect related symptoms (i.e., passive withdrawal, emotional withdrawal, social avoidance) in schizophrenia.
AB - This study investigated changes in cerebral activation related to emotion processing in schizophrenia patients with blunted or flat affect (FA+) during treatment with quetiapine. Using functional magnetic resonance imaging (fMRI), brain activation in 12 FA+ schizophrenia patients during passive viewing of sad film excerpts was studied before and after a median of 5.5-months treatment with quetiapine. Random-effects 'paired sample t-test' analyses of brain activation before quetiapine (contrast=sad-neutral, before-after) revealed significant activation in the brainstem (pons, medulla). After quetiapine, the same contrast showed significant prefrontal activation (BA 9, 10 and 11). Activation of key prefrontal areas involved in emotion processing and significant symptoms improvement as measured by the subjective rating scale and PANSS suggests the potential effect of quetiapine in improving blunted affect related symptoms (i.e., passive withdrawal, emotional withdrawal, social avoidance) in schizophrenia.
KW - Blunted affect
KW - Emotions
KW - Negative symptoms
KW - Prefrontal cortex
KW - Quetiapine
KW - Schizophrenia
KW - fMRI
UR - http://www.scopus.com/inward/record.url?scp=10944242712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10944242712&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2004.08.015
DO - 10.1016/j.pnpbp.2004.08.015
M3 - Article
C2 - 15610941
AN - SCOPUS:10944242712
SN - 0278-5846
VL - 29
SP - 21
EP - 26
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
IS - 1
ER -